Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $0.35, $0.06 better than the analyst estimate of $0.29. Revenue for the quarter came in at $458.71 versus the consensus estimate of $453.4 million.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.